| Jeffrey L Allen, CRNA | |
|
1101 26th St S, Great Falls, MT 59405-5161 | |
| (406) 455-5000 | |
| Not Available |
| Full Name | Jeffrey L Allen |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 1101 26th St S, Great Falls, Montana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245256916 | NPI | - | NPPES |
| 000099336 | Other | MT | BCBS |
| 1245256916 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RN24629 (Montana) | Primary |
| Entity Name | Livingston Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245222306 PECOS PAC ID: 5991613598 Enrollment ID: O20031122000111 |
News Archive
Malaria can complicate the course of disease in poor farmers with landmine injuries in underdeveloped countries, where both malaria and war injuries are frequent causes of illness and death. Tove Heger's doctoral research has charted the extent and effect of malaria on war-injured people and studied the potential for preventing them contracting the disease.
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from a double-blind, placebo-controlled, multiple-dose randomized study of TBR-652 in sixty healthy volunteers.
Findings presented at Digestive Disease Week 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.
The North American Center for Continuing Medical Education, LLC in partnership with HMP Communications, LLC, publisher of EP Lab Digest, today announced that the Electrophysiology Innovations Congress-EP Innovations 2010 will be co-sponsored by the Heart Rhythm Society. Electrophysiology Innovations Congress EP Innovations 2010, the world's premier annual electrophysiology meeting, will take place December 9-11, 2010, at the Washington Hilton in Washington, DC.
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once-daily dosing of the active ingredient at the site of infection.
› Verified 6 days ago
| Entity Name | Butte Pain And Anesthesia Associates, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205869468 PECOS PAC ID: 9133012735 Enrollment ID: O20040206000325 |
News Archive
Malaria can complicate the course of disease in poor farmers with landmine injuries in underdeveloped countries, where both malaria and war injuries are frequent causes of illness and death. Tove Heger's doctoral research has charted the extent and effect of malaria on war-injured people and studied the potential for preventing them contracting the disease.
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from a double-blind, placebo-controlled, multiple-dose randomized study of TBR-652 in sixty healthy volunteers.
Findings presented at Digestive Disease Week 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.
The North American Center for Continuing Medical Education, LLC in partnership with HMP Communications, LLC, publisher of EP Lab Digest, today announced that the Electrophysiology Innovations Congress-EP Innovations 2010 will be co-sponsored by the Heart Rhythm Society. Electrophysiology Innovations Congress EP Innovations 2010, the world's premier annual electrophysiology meeting, will take place December 9-11, 2010, at the Washington Hilton in Washington, DC.
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once-daily dosing of the active ingredient at the site of infection.
› Verified 6 days ago
| Entity Name | Logan Health - Conrad |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467445049 PECOS PAC ID: 8921917501 Enrollment ID: O20040304001137 |
News Archive
Malaria can complicate the course of disease in poor farmers with landmine injuries in underdeveloped countries, where both malaria and war injuries are frequent causes of illness and death. Tove Heger's doctoral research has charted the extent and effect of malaria on war-injured people and studied the potential for preventing them contracting the disease.
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from a double-blind, placebo-controlled, multiple-dose randomized study of TBR-652 in sixty healthy volunteers.
Findings presented at Digestive Disease Week 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.
The North American Center for Continuing Medical Education, LLC in partnership with HMP Communications, LLC, publisher of EP Lab Digest, today announced that the Electrophysiology Innovations Congress-EP Innovations 2010 will be co-sponsored by the Heart Rhythm Society. Electrophysiology Innovations Congress EP Innovations 2010, the world's premier annual electrophysiology meeting, will take place December 9-11, 2010, at the Washington Hilton in Washington, DC.
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once-daily dosing of the active ingredient at the site of infection.
› Verified 6 days ago
| Entity Name | Benefis Hospitals Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780968974 PECOS PAC ID: 1153235296 Enrollment ID: O20100629000044 |
News Archive
Malaria can complicate the course of disease in poor farmers with landmine injuries in underdeveloped countries, where both malaria and war injuries are frequent causes of illness and death. Tove Heger's doctoral research has charted the extent and effect of malaria on war-injured people and studied the potential for preventing them contracting the disease.
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from a double-blind, placebo-controlled, multiple-dose randomized study of TBR-652 in sixty healthy volunteers.
Findings presented at Digestive Disease Week 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.
The North American Center for Continuing Medical Education, LLC in partnership with HMP Communications, LLC, publisher of EP Lab Digest, today announced that the Electrophysiology Innovations Congress-EP Innovations 2010 will be co-sponsored by the Heart Rhythm Society. Electrophysiology Innovations Congress EP Innovations 2010, the world's premier annual electrophysiology meeting, will take place December 9-11, 2010, at the Washington Hilton in Washington, DC.
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once-daily dosing of the active ingredient at the site of infection.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey L Allen, CRNA Po Box 6010, Great Falls, MT 59406-6010 Ph: (406) 455-4477 | Jeffrey L Allen, CRNA 1101 26th St S, Great Falls, MT 59405-5161 Ph: (406) 455-5000 |
News Archive
Malaria can complicate the course of disease in poor farmers with landmine injuries in underdeveloped countries, where both malaria and war injuries are frequent causes of illness and death. Tove Heger's doctoral research has charted the extent and effect of malaria on war-injured people and studied the potential for preventing them contracting the disease.
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from a double-blind, placebo-controlled, multiple-dose randomized study of TBR-652 in sixty healthy volunteers.
Findings presented at Digestive Disease Week 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.
The North American Center for Continuing Medical Education, LLC in partnership with HMP Communications, LLC, publisher of EP Lab Digest, today announced that the Electrophysiology Innovations Congress-EP Innovations 2010 will be co-sponsored by the Heart Rhythm Society. Electrophysiology Innovations Congress EP Innovations 2010, the world's premier annual electrophysiology meeting, will take place December 9-11, 2010, at the Washington Hilton in Washington, DC.
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once-daily dosing of the active ingredient at the site of infection.
› Verified 6 days ago
Thomas Scruggs, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 3010 15th Ave S, Great Falls, MT 59405 Phone: 406-216-8000 | |
Luke Jarvis Jackson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1400 29th St S, Great Falls, MT 59405 Phone: 409-454-2171 | |
Richard W Willey, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1509 29th St S, Great Falls, MT 59405 Phone: 406-771-3500 Fax: 406-771-3502 | |
Mr. Michael A. Mahler, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1101 26th St S, Great Falls, MT 59405 Phone: 406-455-5000 Fax: 406-731-8318 | |
Gary R Howard, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1509 29th St S, Great Falls, MT 59405 Phone: 406-771-3500 Fax: 406-771-3502 | |
Mrs. Robinette Louise Jankiewicz, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1101 26th St. S., Benefis, Great Falls, MT 59405 Phone: 406-731-8755 |